1. Womens’ health and disease
I conduct research in basic pathophysiology in women who are at risk of developing type 2 diabetes and investigate if it’s possible to prevent these women from developing type 2 diabetes.
2. Life science research
I coordinate clinical studies where we are paid by a pharmaceutical company to investigate the effect of the company’s diabetes medicine.
1. Investigation of the incretin effect in women with polycystic ovary syndrome before and after treatment of insulin resistance.
Aim: to evaluate if women with polycystic ovary syndrome and isolated insulin resistance, but normal fasting plasma glucose and normal glucose tolerance, have reduced incretin effect compared to a control group of healthy women.
2. The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitus.
Aim: To investigate the effect of the glucagon-like peptide-1 receptor agonist liraglutide on pathophysiological characteristics and the risk of type 2 diabetes mellitus in women with previous gestational diabetes mellitus.
Collaborators: Elisabeth R. Mathiesen and Peter Damm, Center for pregnant women with diabetes, Rigshospitalet. Jens A. Svare, Department of Gynaecology and obstetrics, Herlev Gentofte Hospital. Tine D. Clausen and Birgit Bødker, Department of Gynaecology and obstetrics, Nordsjællands Hospital. Charlotte Strandberg and Peter M. Gørtz, Department of X-ray and scanning, Herlev Gentofte Hospital. Jens Juul Holst, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Nicklas R. Jørgensen, Department of Clinical Biochemistry, Rigshospitalet Glostrup. Henning Grønbeck, Medical hepato- gastroenterologic department, Aarhus University Hospital
3. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of efpeglenatide on cardiovascular outcomes in type 2 diabetes patients at high cardiovascular risk.
Aim: to investigate if efpeglenatide is noninferior to placebo with regards to cardiovascular events in type 2 diabetes patients at high cardiovascular risk.
4. A 12-week/46-week/52-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic gastroparesis.
Aim: To compare the efficacy of relamorelin with placebo in participants with diabetic gastroparesis with respect to a composite of the following core signs and symptoms of diabetic gastroparesis: nausea, abdominal pain, postprandial fullness and bloating